{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Turnstone Biologics Corp."},"Symbol":{"label":"Symbol","value":"TSBX"},"Address":{"label":"Address","value":"9310 ATHENA CIRCLE,SUITE 300, LA JOLLA, California, 92037, United States"},"Phone":{"label":"Phone","value":""},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The Company is focused on developing tumor infiltrating lymphocytes (TIL) therapies designed to drive clinical benefit and curative outcomes across multiple solid tumors. Its selected TIL approach focuses on selecting and expanding potent tumor-reactive T cells to overcome the limitations of bulk TILs. Its pipeline includes TIDAL-01 and TIDAL-02. Its lead selected TIL product candidate, TIDAL-01, utilizes an unbiased identification and functional screening process to isolate and selectively expand the breadth of tumor-reactive TILs from the patient's tumor. Its next selected TIL program, TIDAL-02, is being designed to encompass a streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function."},"CompanyUrl":{"label":"Company Url","value":"https://www.turnstonebio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Sammy J. Farah","title":"President, Chief Executive Officer & Director"},{"name":"Stewart Abbot","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}